Fluid Pharma is pleased to announce that TAT-FIT™ will be exhibited at three key research and laboratory animal science events this autumn, providing opportunities to connect with researchers and share how our technology can support the refinement of oral dosing in preclinical research. TAT-FIT™ is Fluid Pharma’s, our innovative formulation...

Fluid Pharma continued to build international awareness of Tat-Fit™ by exhibiting at the 47th Belgian Council for Laboratory Animal Science (BCLAS) Annual Symposium, held in Anderlecht, Brussels, on 22–23 April 2026. The symposium brought together laboratory animal science professionals from across Europe, providing an opportunity to discuss the latest advances...

Fluid Pharma is delighted to announce that its research on Tat-Fit™ has been recognised with the Best Poster Prize for Science-Based Welfare Content at the Institute of Animal Technology (IAT) Congress 2026, held from 24–27 March. The award-winning poster, Palatable and Refined Oral Approach to Tamoxifen Dosing for Cre Induction...

Fluid Pharma continued to build momentum in the animal health sector with its participation in the Animal Health, Nutrition & Technology Innovation Europe (AHNTI EU) Summit, held in London from 2–4 March 2026. The event brought together innovators and industry leaders from across the animal health value chain, including biopharma,...

Fluid Pharma is proud to announce the official launch of Tat-Fit™, the first palatable tamoxifen formulation designed specifically for oral dosing in mice for transgenic research. Developed using Fluid Pharma’s proprietary MicroCoat® technology, Tat-Fit™ is a taste-masked micro-pellet formulation that enables stress-free, consistent administration of tamoxifen through standard rodent feed....

Fluid Pharma was honoured to present its pioneering anti-malarial therapy at the UK Parliament on Monday, 8 September, during the event “Innovation to Action: Harnessing UK Research for Global Health Solutions.” The event formed part of a high-level South African parliamentary exchange visit, coordinated by STOPAIDS and WACI Health. It...

Fluid Pharma, in collaboration with the Cancer Research UK Cambridge Institute (CRUK CI), has been awarded a £168K Partnerships and Impact Award from the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). The funded project — “Characterization and Application of Tamoxifen Taste-Masked Beads in Preclinical...

Fluid Pharma’s Artesunate/Amodiaquine (ASAQ) coated micro-pellet combination therapy for paediatric malaria has been included in the World Health Organization (WHO) draft Paediatric Drug Optimisation (PADO) priority list. ASAQ is an artemisinin-based combination therapy (ACT) widely used across low- and middle-income countries (LMICs)—particularly in Sub-Saharan Africa—and forms a key component of...

Mikart and Fluid Pharma enter into a collaboration agreement to manufacture clinical trial materials using proprietary MicroCoat™ technology to advance new therapies.  Mikart, LLC (“Mikart”) a comprehensive contract development and manufacturing organization and Fluid Pharma Ltd announce that they have entered into a collaboration agreement to advance the application of...

Hertfordshire Sept 22: Fluid Pharma Ltd, a licensing and product development company applying its proprietary technologies to advance new therapies for paediatric, geriatric and oral liquid modified release applications, announces a technology partnership with Glatt Pharmaceutical Services to commercialise the MicroCoat™ technology platform within the EU and EAA.  MicroCoat™ is...

Fluid Pharma is pleased to announce that it has won the 2020 CRACK IT Challenge – 39 and has been awarded £100k from the National Centre for Replacement, Refinement and Reduction of Animals in Research (NC3Rs). With the award, Fluid Pharma will develop a method that allows tamoxifen to be...

Fluid Pharma is pleased to announce that it has secured $1.9m of funding from Unitaid as part of new initiative to deliver enhanced malaria treatment to children across Africa. The grant, which is led by Dr Fang Liu at Fluid Pharma, will run over 24 months and will utilise Fluid...

Each year The RSC welcomes applications from entrepreneurs who are developing technologies that have a strong chemistry component and fall within one of the following categories: Health Food & Drink Energy & Environment Enabling Technologies From the application round, 24 finalists were selected to present their technologies to a panel...

Fluid Pharma is pleased to announce that it will be attending and presenting at the upcoming 12th Annual EuPFI conference. Due to the current Covid-19 pandemic, the conference will be held virtually, however Fluid Pharma will be exhibiting and members of our team will be on hand to discuss our...